Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CymaBay Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
Via Benzinga
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800... 
Via Benzinga
Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index climbing to a fresh high during the session. 
Via Benzinga
Topics Economy Stocks
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500... 
Via Benzinga
Topics Stocks
6 Analysts Have This to Say About CymaBay Therapeutics
 
Via Benzinga
Recap: CymaBay Therapeutics Q3 Earnings
 
Via Benzinga
Dow Up Triple Digits, Hits Fresh Highs
Stocks are on the rise today, as investors towards tomorrow's inflation data. 
Via Talk Markets
Topics Economy Stocks
Why is CymaBay (CBAY) Stock Up 25% Today?
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences. 
Via InvestorPlace
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
 
Via Benzinga
Earnings Outlook For CymaBay Therapeutics
 
Via Benzinga
Where CymaBay Therapeutics Stands With Analysts
 
Via Benzinga
Why CymaBay Therapeutics Stock Is Sinking This Week
The stock has given up some of its gains but remains up more than 130% year to date. 
Via The Motley Fool
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue... 
Via Benzinga
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
The company is working on a treatment for primary biliary cholangitis, a liver disease treatment. 
Via Investor's Business Daily
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
The company is working on the first treatment that could make a difference in the itching associated with a liver disease. 
Via Investor's Business Daily
Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
 
Via Benzinga
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
It became increasingly likely that seladelpar will ultimately gain regulatory approval. 
Via The Motley Fool
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. 
Via InvestorPlace
UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
 
Via Benzinga
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
The company is about to reap more money than previously expected from a new capital-raising effort. 
Via The Motley Fool
Why CymaBay Therapeutics Stock Popped Again Today
Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising. 
Via The Motley Fool
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics. 
Via Benzinga
Why CymaBay Therapeutics Stock Is Jumping Today
The momentum continues after CymaBay reported great clinical results on Thursday. 
Via The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
The company is working on a treatment for a liver disease that can cause severe itching. 
Via Investor's Business Daily
Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. Lantronix, Inc. (NASDAQ: LTRX) shares jumped 26.3% to... 
Via Benzinga
Topics Stocks
CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS